So the element around consumer advice or the lack of that consumer input is a known significant gap in regards to the policy consideration but also, I think, the funding prioritisation of pharmaceutical drugs. My question for the Minister is: how are you going to actually measure or ensure that this actually occurs, because that's the case today, and it's not happening. So what confidence can we and consumers out there get in terms of, whether we're talking about rare disorders, or we're talking about type 1 diabetics looking for the provision of funding for continuous glucose monitoring systems, which is the next phase above insulin pumps—what is the ability for those consumers to be able to have a voice as part of that process, and what will change as a result of this legislation, in particular, in clause 64(1)(b), that, actually, will make that a reality? Those are the two points I wish to ask.